Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014

BACKGROUND: Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. However only a tiny proportion of TB patients in the world have access to isoniazid drug susceptibility testing—the widely implemented Xpert MTB/RIF technology only tests for resistance to rifampicin. Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornejo Garcia, Jose Gabriel, Alarcón Guizado, Valentina Antonieta, Mendoza Ticona, Alberto, Alarcon, Edith, Heldal, Einar, Moore, David A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279036/
https://www.ncbi.nlm.nih.gov/pubmed/30513085
http://dx.doi.org/10.1371/journal.pone.0206658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279036/
https://www.ncbi.nlm.nih.gov/pubmed/30513085
http://dx.doi.org/10.1371/journal.pone.0206658

Ejemplares similares